Hims & Hers Health, Inc. Class A Common Stock (HIMS)
55.50
+3.74 (7.23%)
NYSE · Last Trade: Sep 12th, 7:09 PM EDT
Detailed Quote
Previous Close
51.76
Open
51.03
Bid
55.00
Ask
55.02
Day's Range
50.25 - 55.93
52 Week Range
14.53 - 72.98
Volume
35,447,617
Market Cap
10.65B
PE Ratio (TTM)
70.25
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
25,026,296
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the testosterone replacement therapy market.
Businesses with strong free cash flow tend to be more adaptable and resilient.
Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone replacement therapy market by launching a new category in men's health.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market.
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.
Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst actions.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK - August 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) of a class action securities lawsuit.
